- Motley Fool•22 hours ago
MannKind plans to more than double its sales force and air TV commercials plus more to increase Afrezza sales. Will this plan work?
- TheStreet.com•7 days ago
The stock has taken a beating, but users of Afrezza are loyal to the drug.
- 24/7 Wall St.•7 days ago
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
MNKD: Summary for MannKind Corporation - Yahoo Finance
MannKind Corporation (MNKD)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
|Bid||0.64 x 500|
|Ask||0.64 x 1000|
|Day's range||0.63 - 0.67|
|52-week range||0.41 - 2.24|
Trade prices are not sourced from all markets
|PE ratio (TTM)||-1.39|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|